Merck Animal Health Receives FDA Approval of Safe-Guard® AquaSol for Use in Swine

MADISON, N.J. August 4, 2016 – Merck Animal Health (known as MSD Animal Health outside of the United States and Canada) today announced the introduction of Safe-Guard® AquaSol (fenbendazole oral suspension) for use in U.S. swine operations. Safe-Guard AquaSol is indicated for the treatment and control of adult and larval stages of large roundworms, whipworms and kidney worms, as well as adult stages of the small stomach worm, nodular worm and lungworm.
“Reducing parasite burdens improves the health and performance of swine, resulting in improved feed conversion, optimal average daily gain and better group uniformity, as well as minimizing the economic impact of production losses,” said Robyn Fleck, D.V.M., Scientific Sales Affairs, Merck Animal Health. “Safe-Guard AquaSol is unique in that it is the only water delivery approved dewormer that is indicated for the control of the larval stage of roundworms, whipworms and kidney worms. This is critical given that the larvae migrate through body tissues significantly impacting the condition of the animal.”
Safe-Guard AquaSol is produced with an innovative wet-milling technology, which produces a highly stable suspension that can be conveniently administered through drinking water for a three consecutive-day treatment period. Water delivery allows greater flexibility for treatment of pigs at any time from suckling to adult, and the formulation can be easily adjusted to treat any number of swine, from 1 to 10,000. In addition, the product’s smaller particle sizes help to prevent sedimentation and clogged pipes, filters or nipple drinkers.1 The product can be used in both water proportioners and stock tanks.
Safe-Guard AquaSol is available in 1 liter and 1 gallon presentations. For more information about this product, contact your Merck Animal Health sales representative.

Safety Information:

There is a two day pre-slaughter withdrawal period when used according to the product label. Consult your veterinarian for assistance in the diagnosis, treatment and control of parasitism.

About Merck Animal Health

For 125 years, Merck has been a global health care leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit or connect with us on LinkedIn and Twitter at @MerckAH.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (

  • 1. Data on file. Merck Animal Health